POLY MEDICURE LTD.

Poly Medicure Ltd announced an update regarding proceedings before the Hon'ble Delhi High Court concerning a stamp duty matter. Following earlier disclosures about orders from the Office of Collector of Stamps, Revenue Department, Government of NCT of Delhi, the company's writ petition challenging these orders was heard on July 03, 2026. The Hon'ble High Court of Delhi has stayed the operation and execution of the impugned order dated June 15, 2026, until the next hearing date, as no one appeared on behalf of the respondent. The company received the High Court order copy on July 07, 2026.

Poly Medicure Ltd has announced the closure of its trading window for designated persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from July 1, 2026, until 48 hours after the declaration of financial results for the quarter ending June 30, 2026. The specific date for the board meeting to consider these financial results will be communicated separately to the stock exchanges.

Poly Medicure Ltd has announced a rescheduling of its one-on-one virtual investor meetings. The meetings, originally scheduled for Tuesday, June 23rd, 2026, have been moved to Wednesday, June 24th, 2026. The format and venue remain unchanged, with the meetings to be held virtually and at the company's registered office in New Delhi. No Unpublished Price Sensitive Information (UPSI) will be shared during these interactions. This rescheduling is subject to potential changes due to exigencies.

Poly Medicure Ltd has announced a schedule for an investor and analyst one-on-one meeting. The meeting is set to take place on Thursday, June 25th, 2026, at 03:30 PM India Time. The format includes a plant visit at their Faridabad facility. The company has stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions. This schedule is subject to change based on exigencies.

Poly Medicure Ltd has announced a schedule for investor and analyst meetings on June 22nd and 23rd, 2026. The meetings will include a virtual one-on-one with Axis Max Life on June 22nd and a physical one-on-one with Ikigai Asset at the company's registered office on June 23rd. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions. The schedule is subject to change.

Poly Medicure Ltd has received an order from the Office of Divisional Commissioner, Government of NCT of Delhi, imposing stamp duty and penalty totaling ₹2.50 crore in connection with share issuances. The company disputes the order, citing jurisdictional and procedural infirmities, and plans to pursue legal remedies. The order pertains to alleged deficit stamp duty of ₹1.00 crore and a penalty of ₹1.50 crore, though the company argues it has already discharged applicable stamp duties. The company believes it has strong grounds to contest the demand.

Poly Medicure Ltd announced that company officials will participate in a one-on-one meeting with an analyst/investor on Wednesday, June 17, 2026. The meeting will include a plant visit at their Faridabad facility and a one-on-one session. No Unpublished Price Sensitive Information (UPSI) will be shared during the interaction. The schedule is subject to change.

Poly Medicure Ltd has announced a schedule for one-on-one meetings with analysts and investors on Friday, June 12, 2026. The meetings will include a plant visit at their facility in Faridabad, India. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during these interactions. The schedule was confirmed on short notice.

Poly Medicure Ltd has announced a series of one-on-one meetings with analysts and investors scheduled for June 3rd and 4th, 2026. Participants include HSBC Mutual Fund, Quantum Advisors, T. Rowe Price Prudential, and IDFC Asset Management. These meetings will take place at the Grand Hyatt Mumbai and are subject to change. The company will not share any Unpublished Price Sensitive Information during these interactions. The schedule was confirmed on short notice, and the information is also available on the company's website.

Poly Medicure Ltd has appointed Mr. Indranil Mukherjee as Chief Executive Officer for Asia Pacific and India Business, effective June 1, 2026. He will also serve as Senior Management Personnel (SMP) and report directly to the Managing Director. Mr. Mukherjee brings over 30 years of experience in the medical technology sector, including leadership roles at B. Braun and Translumina Therapeutics. His expertise spans critical care, infusion therapy, surgical instruments, and more.